Regeneron Pharmaceuticals Share Price Today
(NASDAQ: REGN)

Name: Regeneron Pharmaceuticals Share Price Today (NASDAQ: REGN) - Regeneron Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Regeneron Pharmaceuticals share price is $599.76 & ₹51,172.72 as on 25 Apr 2025, 2.30 'hrs' IST

$599.76

▲

11.91

(2.03%)

Market is closed - opens 7 PM, 25 Apr 2025

View live Regeneron Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Regeneron Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Regeneron Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Regeneron Pharmaceuticals share price movements

Today's Low: $586.81
Today's High: $601.28
$599.76
2.16%
Downside
Day's Volatility :2.41%
Upside
0.25%
52 Weeks Low: $525.99
52 Weeks High: $1,211.20
$599.76
12.3%
Downside
52 Weeks Volatility :56.57%
Upside
50.48%

Regeneron Pharmaceuticals (REGN) Returns

Period	Regeneron Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-13.0%	-6.0%	0.0%
6 Months	-36.99%	-8.7%	0.0%
1 Year	-33.99%	-3.1%	0.0%
3 Years	-12.87%	0.8%	-9.5%

Regeneron Pharmaceuticals (REGN) Key Statistics

in dollars & INR

Previous Close	$587.85
Open	$590.93
Today's High	$601.28
Today's Low	$586.81
Market Capitalization	$62.9B
Today's Volume	$791.8K
52 Week High	$1211.1999
52 Week Low	$525.99
Revenue TTM	$14.2B
EBITDA	$4.6B
Earnings Per Share (EPS)	$38.35
PE Ratio	15.27
Dividend Yield	0.6%
Profit Margin	31.07%
Quarterly Earnings Growth YOY	-0.21%
Return On Equity TTM	15.95%

How to invest in Regeneron Pharmaceuticals Stock (REGN) from India?

It is very easy for Indian residents to invest directly in Regeneron Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Regeneron Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Regeneron Pharmaceuticals or REGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Regeneron Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Regeneron Pharmaceuticals shares which would translate to 0.001 fractional shares of Regeneron Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Regeneron Pharmaceuticals, in just a few clicks!

Returns in Regeneron Pharmaceuticals (REGN) for Indian investors in Rupees

The Regeneron Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Regeneron Pharmaceuticals investment value today

Current value as on today

₹69,750

Returns

₹30,250

(-30.25%)

Returns from Regeneron Pharmaceuticals Stock

₹32,663 (-32.66%)

Dollar Returns

₹2,413 (+2.41%)

Indian investors sentiment towards Regeneron Pharmaceuticals (REGN)

19.35%

Period: Mar 25, 2025 to Apr 24, 2025. Change in 30 Days versus previous period

Investment in Regeneron Pharmaceuticals Shares from India has grown by 19.35% over the past 30 days, indicating increased transactional activity.

-3%

Period: Mar 25, 2025 to Apr 24, 2025. Change in 30 Days versus previous period

Search interest for Regeneron Pharmaceuticals Stock from India on INDmoney has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Regeneron Pharmaceuticals Stock (REGN Ticker)

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	889	-4.71	0.14%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	1378	-14.30	0.47%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	164	-14.05	0.56%

Global Institutional Holdings in Regeneron Pharmaceuticals

Vanguard Group Inc
8.49%
BlackRock Inc
7.99%
FMR Inc
7.50%
JPMorgan Chase & Co
6.46%
State Street Corp
4.42%
Capital Research & Mgmt Co - Division 3
4.33%

Analyst Recommendation on Regeneron Pharmaceuticals

Rating

Trend

Buy

76%Buy

20%Hold

2%Sell

Based on 34 Wall street analysts offering stock ratings for Regeneron Pharmaceuticals(by analysts ranked 0 to 5 stars)

Analyst Forecast on Regeneron Pharmaceuticals Stock (REGN)

What analysts predicted

Upside of 45.27%

Target:

$871.30

Current:

$599.76

Insights on Regeneron Pharmaceuticals Stock (Ticker Symbol: REGN)

Price Movement
In the last 7 days, REGN stock has moved up by 4.4%
Increasing Revenue
Regeneron Pharmaceuticals, Inc. has shown consistent revenue growth over the last four quarters, increasing from $3.14 billion to $3.78 billion. This represents an average quarterly increase of 5.9%.
Decreasing Net Profit
Regeneron Pharmaceuticals, Inc. has seen a decline in its net profit over the last three quarters. It decreased from $1.43 billion to $917.7 million, averaging a reduction of 19.0% each quarter.
REGN vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 68.7% return, outperforming this stock by 102.7%
REGN vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 54.0% return, outperforming this stock by 68.8%
Price to Sales
Regeneron Pharmaceuticals, Inc. has a Price-to-Sales Ratio of 4.6, meaning investors are willing to pay $4.6 for every $1 of sales the company generates. In comparison, Beone Medicines Ltd has a higher Price-to-Sales Ratio of 7.1, indicating that investors are willing to pay more for every dollar of sales compared to Regeneron.

Regeneron Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Regeneron Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Regeneron Pharmaceuticals (REGN) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Regeneron Pharmaceuticals, Inc.	-8.15%	-36.99%	-33.99%	-12.87%	7.38%
Beone Medicines Ltd	-0.1%	17.79%	68.73%	64.3%	51.92%
Vertex Pharmaceuticals Incorporated	-1.59%	3.06%	23.79%	83.91%	83.35%
Alnylam Pharmaceuticals, Inc.	-9.98%	-14.92%	68.63%	56.35%	69.83%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Regeneron Pharmaceuticals, Inc.	15.27	15.27	0.93	40.58	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	17.95	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.72	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Regeneron Pharmaceuticals, Inc.	Buy	$62.9B	7.38%	15.27	31.07%
Beone Medicines Ltd	NA	$28.7B	51.92%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$126.1B	83.35%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$30.6B	69.83%	NA	-12.37%

Regeneron Pharmaceuticals Dividend announcements

Regeneron Pharmaceuticals Dividends March, 2025
In the quarter ending March,2025. Regeneron Pharmaceuticals has declared dividend of $0.88

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Organization	Regeneron Pharmaceuticals
Employees	15106
CEO	Dr. Leonard S. Schleifer M.D., Ph.D.
Industry	Health Technology

Management People of Regeneron Pharmaceuticals

Name	Title
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply
Mr. Christopher R. Fenimore CPA	Executive VP of Finance & CFO
Ms. Patrice Gilooly	Senior Vice President of Quality Assurance & Operations
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer
Mr. Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis
Mr. Joseph J. LaRosa J.D.	Executive VP, General Counsel & Secretary
Ms. Melissa Lozner	Senior VP & Chief Compliance Officer

Important FAQs about investing in REGN Stock from India :

What is Regeneron Pharmaceuticals share price today?

Regeneron Pharmaceuticals share price today stands at $599.76, Open: $590.93 ; Previous Close: $587.85 ; High: $601.28 ; Low: $586.81 ; 52 Week High: $1,211.20 ; 52 Week Low: $525.99.

The stock opens at $590.93, after a previous close of $587.85. The stock reached a daily high of $601.28 and a low of $586.81, with a 52-week high of $1,211.20 and a 52-week low of $525.99.

Can Indians buy Regeneron Pharmaceuticals shares?

Yes, Indians can invest in the Regeneron Pharmaceuticals (REGN) from India.

With INDmoney, you can buy Regeneron Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Regeneron Pharmaceuticals at zero transaction cost.

How can I buy Regeneron Pharmaceuticals shares from India?

It is very easy to buy Regeneron Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Regeneron Pharmaceuticals (REGN) be purchased?

Yes, you can buy fractional shares of Regeneron Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Regeneron Pharmaceuticals stocks?

To start investing in Regeneron Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.